日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes

KLRG1 细胞耗竭作为成熟 T 细胞淋巴瘤亚型患者的新治疗策略

Bimarzhan Assatova #, Robert Willim #, Christopher Trevisani, Garrett Haskett, Khyati Maulik Kariya, Kusha Chopra, Sung Rye Park, Michael Yevgeniy Tolstorukov, Sean M McCabe, Jessica Duffy, Abner Louissaint Jr, Jani Huuhtanen, Dipabarna Bhattacharya, Satu Mustjoki, Min Jung Koh, Foster Powers, Eliza

Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease

Ph+ 急性淋巴细胞白血病微小残留病需要突变和细胞状态兼容性,并且可作为靶向治疗

Peter S Winter, Michelle L Ramseier, Andrew W Navia, Sachit Saksena, Haley Strouf, Nezha Senhaji, Alan DenAdel, Mahnoor Mirza, Hyun Hwan An, Laura Bilal, Peter Dennis, Catharine S Leahy, Kay Shigemori, Jennyfer Galves-Reyes, Ye Zhang, Foster Powers, Nolawit Mulugeta, Alejandro J Gupta, Nicholas Cali

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1

通过有效降解 ZFP91 和 IKZF1 克服 T 细胞淋巴瘤中的 IMiD 耐药性

Wenchao Wu, Geoffrey M Nelson, Raphael Koch, Katherine A Donovan, Radosław P Nowak, Tayla B Heavican-Foral, Ajit J Nirmal, Huiyun Liu, Lei Yang, Jessica Duffy, Foster Powers, Kristen E Stevenson, Marcus Kenneth Jones, Samuel Y Ng, Gongwei Wu, Salvia Jain, Ran Xu, Sam Amaka, Christopher Trevisani, Ni

Targeted inhibition of CD47-SIRPα requires Fc-FcγR interactions to maximize activity in T-cell lymphomas

靶向抑制 CD47-SIRPα 需要 Fc-FcγR 相互作用才能最大限度地发挥 T 细胞淋巴瘤的活性

Salvia Jain, Alexandria Van Scoyk, Elizabeth A Morgan, Andrew Matthews, Kristen Stevenson, Gail Newton, Foster Powers, Anu Autio, Abner Louissaint, Guillemette Pontini, Jon C Aster, Francis W Luscinskas, David M Weinstock